表紙
市場調査レポート

PharmaPoint:アトピー性皮膚炎 - インドでの薬剤予測と市場分析

PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 293260
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
PharmaPoint:アトピー性皮膚炎 - インドでの薬剤予測と市場分析 PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
出版日: 2013年11月30日 ページ情報: 英文 95 Pages
概要

世界のアトピー性皮膚炎治療薬市場は、過去10年間は大きな変化がなく、市場の成熟化と医薬品のジェネリック化が進んできましたが、今後の10年間は、初めての生物製剤の発売などにより大きく変化していくと考えられています。インド市場の場合、カルシニューリン阻害薬(ブランド/ジェネリック医薬品とも)や全身性ビタミン誘導体の売上高の大幅増加が市場成長の主な促進要因となっていますが、インドの皮膚科医の処方傾向をみる限り、市場は過当競争状態で、かつジェネリック化が進んでいます。

当レポートでは、インドにおけるアトピー性皮膚炎の治療薬に関する最新の研究・開発状況と、関連市場の将来展望とを分析し、疾患の概要や治療法、市場機会とアンメットニーズ、市場規模の動向(今後10年間分)、現在発売中および治験中の主な薬剤のプロファイル、インド市場の現状と今後の方向性などの情報を盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態
    • 病因
    • 病態
  • 兆候

第4章 疾患の管理

  • 診断
  • 治療法の概要
  • インド
    • 診断
    • 臨床診療

第5章 競合企業の評価

  • 概況
  • 競合企業の戦略的評価
  • 製品プロファイル:主要ブランド
    • プロトピック (tacrolimus)
    • エリデル
    • シクロスポリン(多数のジェネリック医薬品の名称つき)
    • アトピー皮膚炎治療に用いられているその他の薬剤クラス

第6章 市場機会とアンメットニーズ

  • 概要
  • アンメットニーズ
    • 重篤で抵抗性のある患者向けの全身薬
    • 患者を階層化し、オーダーメード指揮治療法を可能とするための検査
    • 患者の痒みを効果的に制御する医薬品
    • アトピー性皮膚炎の病態に関する更なる研究
    • 疾患の緩和をもたらす医薬品
    • 患者・介護人の双方のQoL(生活の質)の改善
  • アンメットニーズのギャップの分析
  • 市場機会
    • 重篤で抵抗性のある患者向けの治療設備の拡充
    • 患者の階層化のための予見的検査
    • 患者の掻痒感に対応するための更なる治療オプション

第7章 パイプライン評価

  • 概要
  • 治験段階にある有望な薬剤
    • 第II相のパイプライン製品

第8章 市場の見通し

  • 世界市場の促進・阻害要因
    • 促進要因:中〜重度の疾患の治療用の、最初の生物製剤の上市見通し
    • 促進要因:医療をまた受けていない、重篤で抵抗性のある患者−−未開拓の市場機会
    • 促進要因:2〜3種類のアトピー性疾患を標的とした医薬品−−市場での地位強化の見通し
    • 促進要因:アトピー性皮膚炎−−製薬企業にとって魅力的な患者人口
    • 促進要因:皮膚の保護機能の回復−−疾患管理の主要な目的であり、保湿剤・外用剤のニーズは続く
    • 阻害要因:第一〜第二線の治療法は、安価でジェネリック化した局所薬が大半を占め、それが市場浸透を図る新規企業への妨げとなる
    • 阻害要因:アトピー性皮膚炎の最大の患者部門−−中程度疾患−−もまた、局所療法のほとんどの形態で十分に管理できる
    • 阻害要因:幼児患者−−最大の患者手段で、新製品の安全性基準を引き上げる要素となる
    • 阻害要因:アトピー性皮膚炎の病因の複雑性と多様性−−既存薬剤による治療結果は、どの患者集団でも同一ではない
    • 阻害要因:患者のかなりの割合が、思春前期になって何の治療も受けずにアトピー性皮膚炎が沈静化している
  • インド
    • 市場予測
    • 主要動向
    • 市場促進・阻害要因

第9章 付録

図表一覧

目次
Product Code: GDHC191CFR

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Strong uptake of branded and generic topical calcineurin inhibitors as well as systemic vitamin derivatives will be the key growth drivers, while prescribing behavior of Indian dermatologists from GlobalData's July 2013 survey suggests a highly crowded, genericized market.

Scope

  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in India from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting India Atopic Dermatitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in India

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
  • 4.2. Treatment Overview
  • 4.3. India
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Protopic (tacrolimus)
    • 5.3.2. Elidel
    • 5.3.3. Cyclosporine (numerous generic names)
    • 5.3.4. Other Therapeutic Drug Classes Used in Atopic Dermatitis

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. A Systemic Drug for Severe Recalcitrant Patients
    • 6.2.2. Tests that Stratify Patients and Allow for a Tailored Treatment Approach
    • 6.2.3. A Drug that Effectively Controls Patients' Pruritus
    • 6.2.4. Further Research into the Pathophysiology of Atopic Dermatitis
    • 6.2.5. A Drug that Induces Disease Remission
    • 6.2.6. Improved Quality of Life for Both Patients and their Carers
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Increase Treatment Armamentarium for Severe Recalcitrant Patients
    • 6.4.2. Predictive Tests for Patient Stratification
    • 6.4.3. More Therapeutic Options that Address Patients' Pruritus

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Phase II Pipeline Products

8. Market Outlook

  • 8.1. Global Drivers and Barriers
    • 8.1.1. Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease
    • 8.1.2. Driver: The underserved severe refractory patient segment presents an untapped market opportunity
    • 8.1.3. Driver: A drug that is able to target two or more atopic diseases would gain a foothold in these markets
    • 8.1.4. Driver: Atopic dermatitis presents an attractive patient population for drug developers
    • 8.1.5. Driver: Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents
    • 8.1.6. Barrier: First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market
    • 8.1.7. Barrier: The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy
    • 8.1.8. Barrier: Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products
    • 8.1.9. Barrier: The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups
    • 8.1.10. Barrier: A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy
  • 8.2. India
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Atopic Dermatitis Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Atopic Dermatitis
  • Table 2: Treatment Guidelines for Atopic Dermatitis
  • Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013
  • Table 4: Referral Rates to an Indian Dermatologist, Split by Severity and Specialist Type, 2013
  • Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in India in 2012
  • Table 6: Leading Treatments for Atopic Dermatitis, 2013
  • Table 7: Product Profile - Protopic
  • Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients
  • Table 9: Protopic SWOT Analysis, 2013
  • Table 10: Product Profile - Elidel
  • Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies
  • Table 12: Elidel SWOT Analysis, 2013
  • Table 13: Product Profile - Cyclosporine
  • Table 14: Cyclosporine SWOT Analysis, 2013
  • Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013
  • Table 16: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment
  • Table 17: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013
  • Table 18: Late-Stage Atopic Dermatitis Pipeline, 2013
  • Table 19: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013
  • Table 20: Phase II and Phase I Atopic Dermatitis Pipeline, 2013
  • Table 21: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022
  • Table 22: Sales Forecasts ($m) for Atopic Dermatitis in India, 2012-2022
  • Table 23: Key Event Impacting Sales for Atopic Dermatitis in India, 2012-2022
  • Table 24: Atopic Dermatitis Market in India - Drivers and Barriers, 2012-2022
  • Table 25: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
  • Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022
  • Figure 4: Sales for Atopic Dermatitis in India by Drug Class, 2012-2022
Back to Top